STADA and SBP Group partner on Keytruda biosimilar and up to three additional biosimilar programmes
STADA and SBP Group have launched a strategic biosimilars partnership beginning with a proposed Keytruda biosimilar and providing a framework for up to three additional programmes.
The initial programme covers TQB3570, a proposed pembrolizumab biosimilar, with CTTQ responsible for development, manufacturing and supply and STADA receiving exclusive commercial rights across multiple European and CIS markets.
The agreement also gives the partners a framework for up to three additional oncology and immunology biosimilars, substantially broadening the potential scope of the collaboration.
Field | Content |
Article Type | Deals |
Companies | STADA; SBP Group; CTTQ |
Deal Type | Strategic biosimilars partnership |
Initial Asset | TQB3570 |
Reference Product | Keytruda (pembrolizumab) |
Therapy Areas | Oncology; immunology |
Technology/Modality | Monoclonal antibody biosimilars |
Programme Scope | TQB3570 plus framework for up to three additional biosimilar programmes |
Commercial Territories | European Union; Switzerland; United Kingdom; CIS, with options covering additional territories |
What Happened | STADA and SBP Group launched a strategic partnership initially covering TQB3570, a proposed pembrolizumab biosimilar, with a framework for up to three additional biosimilars. |
Why It Matters | The partnership combines a major biosimilar opportunity around Keytruda with the potential creation of a broader oncology and immunology portfolio. |
Development Responsibilities | CTTQ will develop, manufacture and supply the products while STADA receives exclusive commercial rights in agreed territories. |
Strategic Rationale | The arrangement combines SBP Group and CTTQ's development and manufacturing capabilities with STADA's established European biosimilars commercial infrastructure. |
Potential Impact | The collaboration could create multiple new biosimilar competitors across major oncology and immunology biologic markets. |
Key Takeaway | STADA and SBP Group are building a multi-product biosimilars partnership starting with a proposed Keytruda biosimilar. |
What to Watch | Development progress for TQB3570, regulatory filings and selection of the additional biosimilar programmes. |
Primary Source | STADA |
Relevant Date | 28 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
留言